COVID-19 vaccine response in patients with hematologic malignancy: A systematic review and meta-analysis
Am J Hematol
.
2022 Apr;97(4):E132-E135.
doi: 10.1002/ajh.26459.
Epub 2022 Jan 13.
Authors
Inna Y Gong
1
,
Abi Vijenthira
1
2
,
Stephen D Betschel
1
3
,
Lisa K Hicks
1
4
,
Matthew C Cheung
1
5
Affiliations
1
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
2
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
3
Division of Allergy and Immunology, St. Michael's Hospital, Toronto, Ontario, Canada.
4
Division of Hematology/Oncology, St. Michael's Hospital, Toronto, Ontario, Canada.
5
Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
PMID:
35007350
PMCID:
PMC9011569
DOI:
10.1002/ajh.26459
No abstract available
Publication types
Letter
Meta-Analysis
Systematic Review
MeSH terms
COVID-19 Vaccines
COVID-19* / prevention & control
Hematologic Neoplasms* / therapy
Humans
SARS-CoV-2
Substances
COVID-19 Vaccines